Opster Ltd.
Total Consideration
$23.0M
Purchase-Price Allocation
Goodwill
$15.9M
Contingent Earn-Out
$3.0M
Elastic N.V. — Key Metrics
3 years of history · ending 2025-04-30 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Cash-Flow Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$-1
Book Value Per Share
$9
Free Cash Flow Per Share
$3
Cash Per Share
$7
Revenue Per Share
$14
OCF Per Share
$3
Return on Equity
-13.0%
Return on Assets
-4.5%
Return on Invested Capital
-3.1%
Debt to Equity
0.61
Current Ratio
1.92
Quick Ratio
1.92
Asset Turnover
0.61
Days Sales Outstanding
92.43
Days Payables Outstanding
16.48
R&D / Revenue
24.7%
SBC / Revenue
—
Capex / Revenue
0.3%
Working Capital
$923M
Net Current Asset Value
$265M
Invested Capital
$1.50B
OCF / Net Income
-2.46
FCF / Net Income
-2.42
Accruals Ratio (Sloan)
-14.4%
Net Debt
$-828M
Net Debt / EBITDA
15.97
Interest Coverage
-2.17
Cash Coverage
10.52
Capex Coverage
61.26
Tangible Common Equity
$596M
TCE / Total Assets
23.0%
Goodwill / Total Assets
12.3%
NOPAT
$-43M
Cash ROIC
18.7%
WC / Revenue
62.2%
Capex / D&A
1.40
Reinvestment Rate
-2.3%
Total Payout Ratio
—
Asset Growth vs Revenue Growth
-1.4%
Revenue 5Y CAGR
28.2%
Book Value 5Y CAGR
17.5%
Stock Price (FY-end)
$86
Market Cap
$8.94B
P/E Ratio
172.21
P/S Ratio
6.02
P/B Ratio
9.64
P/TB Ratio
14.98
P/OCF Ratio
33.57
P/FCF Ratio
34.13
Enterprise Value
$8.11B
EV / Sales
5.47
EV / FCF
30.97
FCF Yield
2.9%
Shareholder Yield
—
Buyback Yield
—
R&D Yield
4.1%
Capex Yield
0.0%
Graham Number
$10
Shares Variation (YoY)
-0.3%
Beta (5Y)
1.67
Cost of Equity
12.9%
Cost of Debt (after tax)
3.5%
WACC
12.3%
ROIC - WACC Spread
-15.4%
52W High
$122
52W Low
$70
Trailing Return 1Y
-19.8%
Trailing Return 5Y
41.0%
F-Score (Piotroski)
7.00
Z-Score (Altman)
3.55
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
EPS — Consensus vs Actual
Revenue — Consensus vs Actual
Stock Price on Earnings Dates
Elastic N.V. — Effective Tax Rate ReconciliationNEW
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 25.00% | 25.00% | 25.00% | 25.80% | 25.80% | 25.80% |
| State & Local Income Taxes | — | — | — | -0.20% | -1.50% | -21.80% |
| Foreign Rate Differential | -0.20% | 0.40% | 1.10% | 0.60% | 2.00% | 17.60% |
| Other Adjustments | -0.60% | -2.30% | -3.50% | -1.50% | -0.20% | 0.50% |
| FDII Deduction | — | — | 0.00% | 0.00% | -1.90% | -7.10% |
| Valuation Allowance Change | -57.80% | -120.40% | -46.40% | -31.90% | 1.52% | -1.54% |
| Tax Settlements (Foreign) | — | -1.10% | -0.90% | -1.50% | -2.30% | -8.60% |
| Effective Tax Rate | 1.20% | -6.30% | -3.10% | -8.90% | 1.50% | -2.42% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | −$2.0M | $7.7M | $6.1M | $19.3M | −$184.5M | $76.5M |
| Income Taxes Paid (Cash) | $3.5M | −$423.0K | $4.0M | $11.6M | $24.2M | $22.0M |
Elastic N.V. — M&A AcquisitionsNEW
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Keep Alerting Ltd.
Total Consideration
$10.0M